<prompt> A monoclonal antibody, also called antiangiogenesis agent used in metastatic colo- rectal carcinoma isTrastuzumabRituximabBevacizumabCetoximab  <response>: C. i.e. Bevacizumab 478 - Lippincotts Pharmacology 3rdBEVACIZUMAB - is the first in a new class of anticancer drugs called antiangiogenesis agents. Bevacizumab is approved for use as a first line drug against metastatic colo-rectal cancer and is given with 5- FU- based chemotherapy Most common adverse effects - Hypertension, Stomatitis, and diarrhea.Monoclonal antibodyIndicationAdverse effects TRASTUZUMAB Metastatic breast cancer. Administered with paclitaxel- Congestive heart failure RITUXIMAB Genetically engineered chimeric monoclonal antibody directed against the CD-20 antigen1. Post transplant lymphoma2. Chronic lymphocytic leukemia- Hypotension bronchospasm- Angioedema- Tumor lysis syndromeCETUXIMAB Antineoplastic effect Treat colorectal cancer Used with irinotecan- Difficulty in breathing LOW BPAbciximab is platelet inhibitor 